Table 1. Clinical and neuropathological characteristics of study subjects.
| ADD (n = 66) | ADD/DLB (n = 29) | ADLB N = 30) | PDD+AD (n = 21) | PDD-AD (n = 27) | Control (n = 84) | p-value | |
|---|---|---|---|---|---|---|---|
| Age (yrs)1 | 88.2 (6.9) | 85.1 (7.4) | 87.0 (7.6) | 83.2 (4.7) | 78.2 (7.5) | 86.7 (6.9) | < 0.0001 |
| Gender (M/F) | 50/46 | 22/7 | 23/7 | 13/8 | 22/5 | 38/46 | < 0.01 |
| Last MMSE score2 | 18.3 (8.3) | 17.1 (7.0) | 14.6 (8.3) | 20.0 (5.5) | 21.1 (5.5) | 28.3 (1.4) | < 0.0001 |
| Last UPDRS Score3 | 16.5 (15.9) | 23.7 (20.0) | 15.8 (13.8) | 41.8 (16.6) | 43.2 (17.1) | 8.5 (8.8) | < 0.0001 |
| Plaque Score4 | 12.98 (2.42) | 11.48 (3.85) | 14.0 (0.99) | 11.3 (3.7) | 1.44 (2.7) | 5.21 (5.68) | < 0.0001 |
| Tangle Score5 | 10.77 (3.45) | 9.24 (3.86) | 12.4 (2.7) | 6.5 (2.3) | 5.3 (2.8) | 4.82 (2.51) | < 0.0001 |
| LB Score6 | 3.28 (6.91) | 21.19 (5.52) | 10.8 (8.8) | 32.0 (6.6) | 27.6 (5.1) | 0 | < 0.0001 |
Means and standard deviations are shown. ADD = Alzheimer’s disease dementia; DLB = dementia with Lewy bodies; MMSE = last Mini Mental State Examination score; UPDRS = last Unified Parkinson’s Disease Rating Scale motor score (part 3 score, off medications); Plaque Score and Tangle Score = summary regional brain density scores with maximum scores of 15. LB Score = summary regional brain Lewy-type synucleinopathy density score with a maximum score of 40. All values in the p-value column are for one-way analysis of variance except for gender, where chi-square analysis was done.
1. Post-hoc paired Bonferroni significance testing significant (p<0.05) for PDD+AD and PDD-AD vs all other groups.
2. N = 29 for ADLB; Post-hoc paired Bonferroni significance testing significant (p<0.05) for all groups vs control and for ADLB vs PDD+AD and PDD-AD.
3. N = 94, 27, 29, 15, 21 and 82 for ADD, ADD/DLB, ADLB, PDD+AD, PDD-AD and control, respectively. Post-hoc paired Bonferroni significance testing significant (p<0.05) for all groups vs control except ADD vs control, and significant for ADD, ADLB and ADD/DLB vs PDD+AD and PDD-AD.
4. Post-hoc paired Bonferroni testing significant (p < 0.05) for all groups vs control and for ADD and for all groups vs PDD-AD.
5. N = 95 for ADD; Post-hoc paired Bonferroni testing significant (p < 0.05) for PDD+AD, PDD-AD and control vs ADD and ADD/DLB.
6. N = 92, 26, 28, 20 for ADD, ADD/DLB, ADLB, PDD+AD respectively; Post-hoc paired Bonferroni testing significant (p < 0.05) for control and ADD vs all groups and for ADLB vs ADD/DLB, PDD+AD and PDD-AD.